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Abstract
Introduction Tacrolimus is a calcineurin inhibitor used as
an immunosuppressant drug in solid organ transplantation,
and is mainly metabolized by cytochrome P450
(CYP) 3A4 and CYP3A5. Studies have shown an associ-
ation between the CYP3A5 genotype and tacrolimus dose-
adjusted trough concentrations. Variants in the genes
PPARA, POR and CYP3A4 have recently been shown to
influence tacrolimus metabolism. Furthermore, pharma-
cokinetic interaction between corticosteroid treatment and
tacrolimus has been shown. In the present study, we
investigated a potential association between CYP3A5*3,
PPARA c.209-1003G[A, POR*28 and CYP3A4*22 and
dose-adjusted tacrolimus trough concentrations in a pri-
marily corticosteroid-free ([85%) population of Danish
pediatric and adult kidney transplant recipients.
Methods Seventy-two patients receiving treatment with
oral tacrolimus were genotyped using real-time polymerase
chain reaction and Primer-Probe Detection. Tacrolimus
trough concentrations, corresponding doses and covariates
were retrospectively collected from the patients’ medical
charts.
Results It was confirmed that CYP3A5*1 wild-type carriers
had lower median dose-adjusted tacrolimus trough con-
centrations compared with noncarriers. Adults had 56 and
77% lower trough concentrations at 6 weeks (p = 0.0003)
and 1 year, respectively (p\ 0.0017), and, similarly,
children had 65 and 39% lower median concentrations,
with p values of 0.006 and 0.011, respectively. No asso-
ciation was found for PPARA c.209-1003G[A, POR*28,
or CYP3A4*22. An association between the PPARA c.209-
1003G[A genotype and an increased number of infections
with cytomegalovirus (CMV) within the first year was
identified (p\ 0.05). Only 29% of trough concentrations
measured between 2 and 12 weeks post-transplantation
were on target.
Conclusion This study shows that the known association
of the CYP3A5 genotype with tacrolimus dose-adjusted
trough concentrations has the same impact in a corticos-
teroid-sparse population. The association between PPARA
variance and infections with CMV will need further
investigation.
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Key Points
Pediatric and adult cytochrome P450 (CYP) 3A5
expressers need a higher dose of tacrolimus
compared with nonexpressers.
Corticosteroid avoidance does not affect the well-
known lower dose-adjusted trough concentrations
among adult and pediatric CYP3A5 expressers
compared with nonexpressers.
No association between CYP3A4*22, PPARA c.209-
1003G[A and POR*28 and tacrolimus dose-
adjusted trough concentrations was identified.
The PPARA variant allele was associated with an
increased number of cytomegalovirus infections.
Only 29% of tacrolimus measurements were on
target in weeks 2–12.
1 Introduction
Since the beginning of the 1980s, the calcineurin inhibitors
(CNIs) cyclosporine and tacrolimus have been essential for
immunosuppression in solid organ transplantation. They
both inhibit the calcineurin phosphatase activity, which
results in reduced production of interleukin (IL)-2. Their
introduction has led to considerable improvement in graft
survival rates, and it has been shown that tacrolimus is
related to a reduced risk of rejection [1]. Tacrolimus was
first marketed in 1994 and has since then replaced cyclos-
porine as standard of care. The half-life of tacrolimus is
6–21 h and bioavailability is 25%, but with great interindi-
vidual variation [2, 3]. Tacrolimus is metabolized by cyto-
chrome P450 (CYP) 3A4 and CYP3A5, and is a substrate
for the efflux transporter P-glycoprotein. Tacrolimus expo-
sure is typically managed by therapeutic drug monitoring
(TDM) using trough concentration (C0) order to ensure
concentrations sufficiently high for adequate immunosup-
pression and, at the same time, sufficiently low to reduce the
risk of adverse reactions, including nephrotoxicity.
Genetic factors are thought to play a significant role in the
variability of the pharmacokinetics of tacrolimus. Research
in this area might be of particular benefit in the initial phase,
where tacrolimus steady-state is not reached and TDM is
therefore of limited value. CYP3A5*1 carrier status has thus
been demonstrated to cause increased tacrolimus clearance
with lower dose-adjusted trough concentration (C0/D),
whereas the most frequent variant of the gene CYP3A5*3 is
associated with the lack of gene expression and the loss of
functioning protein [4–9]. Recently, the CYP3A4*22
variant, with an allele frequency of 3–5% in Caucasians, has
also been suggested to affect tacrolimus [10, 11]; however,
any impact of this variant remains to be demonstrated.
Peroxisome proliferator-activated receptor-alpha (PPARA)
is a receptor protein in the cell nucleus and is encoded by the
gene of the same name. PPARA regulates genes involved in
the transport, binding, and activation of fatty acids, includ-
ing CYP3A. The variants c.209-1003G[A (rs4253728,
allele frequency 18–30% in Caucasians) and
c.208?3819A[G (rs4823613, allele frequency 20–30% in
Caucasians) have thus been reported to explain up to 8–9%
of variability in the hepatic portion of CYP3A activity [12].
PPARA variants could therefore theoretically affect tacro-
limus dose requirements. CYP oxidoreductase (POR) is a
protein with electron donor capacity important for the
microsomal CYP system [13], thereby possibly influencing
the activity of CYP3A. The most common variant of the
POR gene is the POR*28 allele (rs1057868, allele frequency
30% in Caucasians). Carriers of this allele have been
reported to have up to 15% lower tacrolimus C0/D in one
study [7], but no effect in others [14, 15].
Progress in this field is evident, as demonstrated by the
guideline recently published by the Clinical Pharmacoge-
netics Implementation Consortium (CPIC) [16]. CYP3A5
genotyping is not routinely recommended, but dose
adjustments are recommended in cases where the CYP3A5
genotype is already known. Progress is largely based on
studies that include transplant recipients concomitantly
treated with corticosteroids. Corticosteroids have been
shown to interact with tacrolimus concentration/dose
ratios, possibly by enzyme-specific induction of CYP3A
[17, 18]. We therefore found it relevant and convenient to
conduct this study at our institution, which has a long
tradition of offering corticosteroid-free transplantation.
The aim of this retrospective studywas to assess the effects
of the CYP3A5*3¸ PPARA c.209-1003G[A, POR*28 and
CYP3A4*22 alleles on tacrolimus C0/D, early rejection, and
infection in a corticosteroid-sparse kidney transplant patient
population consisting of both children and adults. We
hypothesize that carriers of CYP3A5*3, PPARA c.209-
1003G[AandCYP3A4*22will havehigher tacrolimusC0/D,
while carriers of POR*28 will have lower tacrolimus C0/D.
Furthermore, if the immunosuppression is affected by geno-
type, a significant difference in the number of infections and
rejections between genotypes might be present.
2 Patients and Methods
2.1 Patients and Recruiting
We recruited pediatric and adult renal transplant patients
from the Department of Nephrology, Odense University
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Hospital, Odense, Denmark, who were treated with tacro-
limus twice daily. Patients or their legal guardian provided
both written and oral consent to participate in the study.
The study adhered to the Declaration of Helsinki and was
approved by the Regional Ethics Committee (VEK #S-
20140169). Blood samples for genotyping were initially
collected from blood that was left from routine blood
sampling that was part of planned outpatient clinic visits;
however, the procedure proved inefficient and the protocol
was amended to also include transplanted patients admitted
to the ward. Blood was stored at -20 C within 24 h of
collection.
2.2 Data Collection
Date of transplantation, donor status, height, weight, and
other characterizations of the patients were extracted from
the medical charts. This also included biochemical results
and blood tacrolimus trough concentrations, as well as
medication history. Tacrolimus was analyzed using an
immunoassay at the hospital central laboratory as part of
routine care. Concurrent medication was screened for the
following CYP3A modulators: HIV antivirals, barbiturates,
carbamazepine, enzalutamide, modafinil, oxcarbazepine,
phenytoin, pioglitazone, rifabutin, rifampin, troglitazone,
clarithromycin, itraconazole, ketoconazole, nefazodone,
suboxone, telithromycin, aprepitant, erythromycin, flu-
conazole, verapamil, diltiazem, and cimetidine. Early graft
rejections were defined as any biopsy-proven rejections
within 1 year of transplantation, and tacrolimus blood
concentrations were determined at the central hospital
laboratory as part of routine patient care. We defined early
and late tacrolimus exposure as the blood concentration
trough value measured exactly by 6 and 52 weeks after
transplantation, respectively. If no tacrolimus concentra-
tion had been taken that day, the nearest available value
was used. Furthermore, if no concentration was available
on the date ±10 days for early exposure, and ±20 days for
late exposure, it was recorded as missing. Trough con-
centrations were classified as being either under, on, or
over target for the relevant interval after transplantation,
with reference to the current department guideline (see
Online Resource Table S1).
Additionally, Epstein–Barr virus (EBV), and cytome-
galovirus (CMV) pretransplant serology status was recor-
ded, along with the number of infections within the first
year post-transplantation. An episode of infection was
defined as at least two consecutive measurements of[1000
viral DNA copies in blood samples (using polymerase
chain reaction [PCR]). If a patient had a negative blood test
while receiving antiviral treatment, but then received pos-
itive results when the antiviral treatment was discontinued,
this was considered to be the same episode of infection.
Separate episodes of infection were defined to require the
patient to have a period of 3 months with negative results
in-between positive results, while not receiving antiviral
treatment for that period.
2.3 DNA Analysis
DNA extraction was performed using the Maxwell 16 Pro-
mega andMaxwell 16 Blood DNA Purification Kit. Briefly,
the blood was treated with proteinase K and lysis buffer, and
kept at 56 C to lessen the amount of protein in the blood
samples; however,DNAextraction provedmost successful by
omitting the proteinase K. Genotyping was performed using
real-time PCRwithAppliedBiosystemsStepOnePlus, using
StepOneSoftwarev2.3 andMicroAmpFast 96-WellReaction
Plates with TaqMan predesigned commercial genotyping
assays. Genotype calling is semi-automatic. The specific
assays used were rs776746 (C__26201809_30) for
CYP3A5*3, rs4253728 (C__31052401_10) for PPARA
c-209-1003G[A, rs1057868 (C__8890131_30) for POR*28,
and rs35599367 (C__59013445_10) for CYP3A4*22.
2.4 Statistical Analyses
The effect of genotype on tacrolimus was assessed by
comparing steady-state tacrolimus trough concentration
corrected for dose (C0/D) across groups; steady-state was
assumed after 5 days of constant dosing. Analyses were
performed using STATA/IC14 (StataCorp LP, College
Station, TX, USA), and associations between tacrolimus
C0/D and variant genotypes and covariates were assessed
using nonparametric analyses (Wilcoxon rank-sum test).
Patients with rare homozygous genotypes were pooled with
the heterozygous patients. No formal power calculation
was performed prior to the study; however, similarly sized
studies have previously demonstrated an impact of
CYP3A5 genotype on tacrolimus trough concentrations in
corticosteroid-treated populations. A p value\0.05 was
considered indicative of statistical significance.
3 Results
3.1 Patients
A total of 84 patients were initially included, however 12
were later excluded—two because they were treated with
cyclosporine, and ten because data were not available from
their medical charts. In total, 72 patients were eligible for
analysis (see Table 1 for the demographic characteristics of
both children and adults). No patients used any of the listed
CYP3A modulators. Sex, age at transplantation, body mass
index, height, weight, donor status, and smoking status did
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not significantly correlate to tacrolimus C0/D and were
therefore excluded from further analyses.
3.2 Genotypes and Tacrolimus Dose-Adjusted
Trough Concentrations
Genotyping was carried out in duplicate. The results were
consistent for all patients and for all genotypes, except for
one patient where a third analysis of CYP3A5 was carried
out. Genotype and allele frequencies of all investigated
variants are shown in Table 2. All gene variants were in
Hardy–Weinberg equilibrium. The group of combined
CYP3A5*1 allele carriers had 63% lower median tacroli-
mus C0/D compared with homozygote carriers of the
CYP3A5*3 allele at 6 weeks post-transplantation (1.33 vs.
3.56 ng/ml/mg, p\ 0.0001). The statistically significant
difference remained in a sensitivity test without corticos-
teroid-using patients (data not shown). For 1 year post-
transplantation, CYP3A5*1 carriers had 62% lower median
tacrolimus C0/D compared with homozygote carriers of the
CYP3A5*3 allele (1.34 vs. 3.53 ng/ml/mg, p = 0.0001).
Again, the significant difference remained after removing
patients using corticosteroids. Analyses of children and
adults separately showed a similar impact of CYP3A5*1
(see Tables 3 and 4 and Fig. 1). Stratified for the CYP3A5
genotype, no significant difference in C0/D was observed
between children and adults.
Neither PPARA c.209-1003G[A nor POR*28 showed
any association with tacrolimus C0/D at 6 weeks or 1 year
following transplantation. As with CYP3A5, carriers of the
investigated variant alleles (G/A and A/A for PPARA; *1/
*28 and *28/*28 for POR) were grouped together and
compared to patients who were homozygous for the non-
variant alleles to assess the potential effect of carrying at
least one variant, but no differences were detected. Addi-
tionally, it was assessed whether the presence of a POR*28
allele among CYP3A5*1 carriers would show an effect on
tacrolimus C0/D, but no significant effect was found.
Interestingly, patients heterozygous for the CYP3A4*22
allele (adults plus children) had 177% higher median
tacrolimus C0/D compared with homozygote wild-type
Table 1 Demographic data of
children (defined as\18 years
of age at the time of
transplantation) and adults
Demographic Adults (n = 52) Children (n = 20)
Male/female (n) 30/22 12/8
Age at transplantation, years [median (range)] 52 (22–71) 9 (1–16)
Height 6 weeks after transplantation, cm [median (range)] 171 (149–191) 127 (81–174)
Weight 6 weeks after transplantation, kg [median (range)] 77 (37–117) 24 (11–48)
Living donor (n) 28 8
Corticosteroids at 6 weeks (%) 15 10
Mycophenolate mofetil at 6 weeks (%) 89 86
Corticosteroids at 1 year (%) 16 0
Mycophenolate mofetil at 1 year (%) 100 100
Rejections within the first yeara (n) 4 0
CMVb infections (n) 11 4
EBVb infections (n) 2 7
BKVb infections (n) 3 1
CMV cytomegalovirus, EBV Epstein–Barr virus, BKV BK virus
a Data available for 64 patients, respectively
b Data available for 61 patients, respectively
Table 2 Genotypes of 72 adult
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carriers at 6 weeks post-transplantation, but the result was
not statistically significant (p = 0.10). No trend was
detected at 1 year post-transplantation.
A total of 648 tacrolimus concentrations were registered
between 2 and 12 weeks after transplantation. No signifi-
cant difference was observed between any of the investi-
gated genotypes and the percentage distribution of
tacrolimus trough concentrations under, on, or over des-
ignated targets (Fig. 2). The overall distribution was 167
(26%) under target, 186 (29%) on target, and 295 (46%)
over target, with no difference between children and adults.
3.3 Infection and Graft Rejection
Overall, 61 patients had data available regarding virus
infections within the first year following transplantation
(Table 1). No association between CYP3A5*3,
CYP3A4*22, or POR*28 variant alleles and infection
within the first year following transplantation was found;
however, a potential association between the PPARA
c.209-1003G[A variant allele and the number of CMV
infections was identified. Carriers of the variant allele also
more frequently had at least one episode of CMV infection
(p value\0.05, Fishers exact test). Acute biopsy-proven
rejection within the first year was 6.3% (n = 64, four
adults). No association was found between variant alleles
and the number of rejections within the first year.
4 Discussion
We assessed the effect of sequence variants in CYP3A5,
CYP3A4, PPARA, and POR on tacrolimus trough con-
centrations in a mostly ([85%) corticosteroid-free popu-
lation of adult and pediatric kidney transplant patients.
Carriers of the CYP3A5*1 allele had between 39% and
77% lower median tacrolimus dose-adjusted trough con-
centrations (C0/D) than noncarriers (p B 0.01). This study
Table 3 Tacrolimus dose-adjusted trough concentrations in adults and children across genotypes 6 weeks after kidney transplantation
Genotype Tacrolimus trough (C0/D; ng/mL/mg)
[median (range)]




*1/*1 and *1/*3 1.31 (0.89–3.94) 8
*3/*3 3.0 (1.13–14.2) 44 0.0003
PPARA
G/G 2.76 (1.13–12.9) 29
G/A ? A/A 2.94 (0.89–14.2) 23 0.73
POR
*1/*1 3.94 (0.89–14.2) 27
*1/*28 ? *28/*28 2.35 (1.13–12.9) 25 0.36
CYP3A4
*1/*1 2.76 (0.89–14.2) 49
*1/*22 5.15 (2.76–12.6) 3 0.24
Children
CYP3A5
*1/*1 and *1/*3 1.42 (1.08–1.85) 4
*3/*3 4.01 (1.24–30.0) 16 0.0061
PPARA
G/G 3.96 (1.33–10.1) 9
G/A ? A/A 2.32 (1.08–30.0) 11 0.85
POR
*1/*1 3.13 (1.08–30) 16
*1/*28 ? *28/*28 2.91 (1.24–17.2) 4 0.71
CYP3A4
*1/*1 2.73 (1.08–30) 19
*1/*22 10.1 1 NA
CYP cytochrome P450, NA not applicable, POR cytochrome P450 oxidoreductase, PPARA peroxisome proliferator-activated receptor-alpha
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confirms the importance of CYP3A5 gene variants on
tacrolimus trough concentrations previously demonstrated
[4–8]; however, with the present study we show that the
effect of CYP3A5 genotype on tacrolimus is also present in
a mostly corticosteroid-free population, which, to our
knowledge, has not been demonstrated before. Thervet
et al. [19] reported that patients who received a genotype-
specific tacrolimus dose obtained target concentrations
faster than control patients. Current guidelines do not
recommend pre-emptive genotyping; however, dosing
adjustments are recommended in cases where the genotype
is known already [16].
No effect of PPARA c.209-1003G[A on tacrolimus C0/
D was found in this study, which is in accordance with the
studies by Kurzawski et al. [14] and Bruckmueller et al.
[15], but in contrast to Lunde et al. [7], who reported 19%
higher tacrolimus C0/D among PPARA variant carriers in a
study with 123 Norwegian kidney transplant patients.
These mixed results warrant further investigation.
Furthermore, this study found no effect of the investi-
gated POR genotype variants on tacrolimus C0/D, which is
in contrast to Lunde et al. [7], who found that patients with
POR*28 variant alleles showed 15% lower tacrolimus C0/
D. Several other studies found that POR*28 polymor-
phisms significantly lowered tacrolimus C0/D among
CYP3A5*1 carriers [4, 20], however this association was
not shown by Lunde et al. In addition, we failed to find any
association between POR*28 ? CYP3A5*1 and tacrolimus
C0/D; however, this could be explained by the low number
of CYP3A5*1 allele carriers (n = 12) in this study. No
significant effect of the CYP3A4*22 variant allele was
found, although it might be argued that a trend for higher
C0/D might be possible (177% increase, p = 0.10). This
result might be limited by the fact that only four patients
carried the CYP3A4*22 allele. Other studies found no
effect of CYP3A4*22 polymorphism [7, 15, 21], while one
study found that significantly less patients carrying a
CYP3A4*22 allele reached target concentrations of tacro-
limus within the first 10 days following transplantation
[10]. Certainly, this association demands further
elucidation.
In an exploratory analysis of data from 61 patients with
available infection data, PPARA c.209-1003G[A was
found to be significantly associated with the number of
CMV infections within the first year following transplan-
tation. For the other genes, no other association was found
between genotype and the number of infections with CMV,
EBV or BKV within the first year. Since PPARA was not
associated with high tacrolimus concentrations, over-im-
munosuppression cannot explain an increased risk of
infections. Moreover, if such an effect was present, carriers
of the wild-type CYP3A5 variant would also have an
increased risk of infections, but this was not observed. It
could be speculated that PPARA possibly influences drug
exposure at the tissue level without measurable impact on
plasma kinetics, but the possibility of a spurious result must
also be considered.
No association between genotype and the distribution of
tacrolimus measurements within weeks 2–12 was found,
which was somewhat surprising as we expected carriers of
the CYP3A5*1 allele to have more measurements below
target relative to homozygous CYP3A5*3 carriers. How-
ever, there is certainly room for improvement, with less
than one-third of measurements actually being on target.
This might suggest that genotype-adjusted dosing in the
initial phase could be a potential improvement. The small
sample size and retrospective design might have limited the
investigated associations across this study. CYP3A5*1 and
CYP3A4*22 allele frequencies in Caucasians are quite low
and could influence the results.
This study used retrospectively collected tacrolimus
trough concentrations only. Drug monitoring using only
Table 4 Tacrolimus dose-adjusted trough concentrations in adults











*1/*1 and *1/*3 1.03 (0.25–3.27) 6
*3/*3 4.53 (0.88–11.4) 31 0.0017
PPARA
G/G 3.4 (0.25–7.5) 20
G/A ? A/A 3.2 (0.74–11.4) 17 0.55
POR
*1/*1 3.53 (0.74–11.4) 19
*1/*28 ? *28/*28 3.23 (0.25–7.5) 18 0.94
CYP3A4
*1/*1 3.23 (0.88–11.4) 36
*1/*22 3.53 1 NA
Children
CYP3A5
*1/*1 and *1/*3 1.69 (0.60–2.0) 4
*3/*3 2.79 (1.73–5.4) 14 0.0107
PPARA
G/G 2.2 (1.48–5.0) 9
G/A ? A/A 2.3 (0.6–5.4) 9 0.83
POR
*1/*1 2.2 (0.6–5.0) 15
*1/*28 ? *28/*28 2.32 (2–5.4) 3 0.41
CYP3A4
*1/*1 2.2 (0.6–5.4) 17
*1/*22 3.5 1 NA
CYP cytochrome P450, NA not applicable, POR cytochrome P450 oxi-
doreductase, PPARA peroxisome proliferator-activated receptor-alpha
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these concentrations is not ideal because correlation with
area under the concentration–time curve (AUC) can be
elusive, and treatment failures also occur within targeted
tacrolimus concentration ranges. Future pharmacogenetic
studies may want to prioritize the collection of full AUC
data if possible. This study was designed to assess the
influence of genotypes separately. A more powerful study
might also have included analyses of combinations of
genotypes. Another limitation to this study is the lack of
formal registration of episodes of diarrhea, which is well-




concentrations (C0/D) in adults
6 weeks after kidney
transplantation. Boxes delimit
the upper and lower quartile and
median, the outliers are[1.5
times the interquartile range
from the quartiles, and the
whiskers mark the extreme






Fig. 2 Distribution of
tacrolimus trough
concentrations under target, on
target, or above target
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5 Conclusion
This study confirms the impact of CYP3A5 variant alleles
on tacrolimus dose-adjusted trough concentrations in a
largely corticosteroid-free population. We showed that less
than one-third of the measured trough concentrations of
tacrolimus were on target between weeks 2 and 12 after
transplantation, independent of genotype. No other effect
of genotype on tacrolimus dose-adjusted trough concen-
trations was found. The potential effect of PPARA c.209-
1003G[A on the number of CMV infections within the
first year will need further prospective study with a larger
sample size.
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